Haematologist | St Vincent’s Hospital Melbourne | Focus: Myeloma & AL amyloidosis & Immunotherapy |Collaborator: Mayo Clinic, ALLG, AAN. Views are my own.
Joined November 2024
- Tweets17
- Following82
- Followers25
- Likes17
Matthew Rees retweeted
Congrats @MattReesMD et al for getting this to finish line!
Link to @AjHematology paper:
onlinelibrary.wiley.com/doi/…
Matthew Rees retweeted
American Journal of Hematology | Long term disease free survival in multiple myeloma Almost 10 percent of symptomatic patients in our series are free of progression at 15 years from initiation of treatment Cure is possible!! onlinelibrary.wiley.com/doi/…
Matthew Rees retweeted
In a recent interview, @MattReesMD provided insight into a multicenter retrospective study assessing the safety & efficacy of BCMA-directed CAR-T in patients with systemic AL #amyloidosis & concurrent #MultipleMyeloma.
Watch it here: 👉 ow.ly/Icgx50XRUfc
#MMSM #Myeloma #CARTCell #ImmunoOnc #ASH25 #HemOnc
New in Haematologica: HBV reactivation reported during bispecific therapy despite negative anti-HBc at baseline. Important implications for MM screening.
haematologica.org/article/vi… @HangQuach1
42
Matthew Rees retweeted
Updated mSMART guidelines on treatment of newly diagnosed myeloma.
Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant.
msmart.org/mm-treatment-guid…
Matthew Rees retweeted
CELMoDs: new class of myeloma #MMsm drugs or just elongated IMiDs?
My take (thanks @Mohty_EBMT for invite!):
⬆️ ⬆️ MRD-neg, RDI (tolerability), T-cell fitness... ∆ profound enough that I'd want "% CELMoD-exposed" listed in future Table 1s of other Rx.
So... different! QED 😉
New @AlbertYunes study: EBV+ polymorphic B-cell LPD (NOS) — first real-world cohort outside the transplant setting.
🧍♂️31 pts | Strong responses to rituximab ± immunosuppression reduction.
🧠 CNS cases can remit; rebiopsy crucial at relapse.
🔗 nature.com/articles/s41408-0…
Matthew Rees retweeted
There are results we are not always "happy" to share.
This is the case for the burnout survey among hematology professionals.
Burnout is common and driven by modifiable systemic factors, not individual failings. It's time to act !
Please share.
onlinelibrary.wiley.com/doi/…
Matthew Rees retweeted
Excited to share our multi-institutional study on ALK+ Large B-cell lymphoma in @AjHematology :
Outcomes remain poor with intensified chemo and consolidative ASCT. Select durable remissions occurred with biologically targeted therapies & allo-SCT
onlinelibrary.wiley.com/doi/…
Matthew Rees retweeted
I am very proud 🙌🏻 of all the #CRTH 2025 scholars for their commitment and hard work. I hope I’ve made a positive impact in their careers as clinical researchers 👩⚕️🧑⚕️ in #hematology 🩸. I wish them all the best and great success!!
On behalf of EHA, we would like to extend our congratulations to the 2025 CRTH cohort for finishing their training program! Interested to join CRTH 2026? Applications are now open until September 16th. Don't miss out! 👉 eha.fyi/CRTH
Matthew Rees retweeted
haematologica.org/newsletter…
New in @Haematologica: early post-chemo AL BM amyloid plaques of pts in >=vgpr show ↓ immunoglobulins & ↑ complement + SAP. Anti-fibril mAbs may lose efficacy post-FLC clearance. Complement activation may worsen toxicity. #Amyloidosis 1/
Matthew Rees retweeted
Real-world data confirms: adding daratumumab to CyBorD in AL amyloidosis improves outcomes.
✅ Higher VGPR+ (78% vs 60%)
✅ Fewer early deaths (6-mo: 8.8% vs 16.3%)
✅ Better 2-yr OS (82% vs 70%)
Best OS boost in stage II.
#amyloidosis #mmsm pubmed.ncbi.nlm.nih.gov/4045…
Matthew Rees retweeted
🫀 In AL #amyloidosis, deeper cardiac responses (CarR) drive survival—but what predicts them? High BM plasma cells ≥20%, kappa isotype, & HR FISH → faster, deeper CarR—independent of hematologic response. Suggests light-chain toxicity matters.pubmed.ncbi.nlm.nih.gov/4040…
Matthew Rees retweeted
In a study of 130 AL #amyloidosis patients with liver involvement, hepatic response rose from 28% at 6 mo to 48% at 24 mo. High baseline ALP (≥4× ULN), deeper hematologic response, kappa type, and frontline ASCT were key predictors of response pubmed.ncbi.nlm.nih.gov/4050…
Matthew Rees retweeted
Characteristics & outcomes of incidentally diagnosed large B cell #lymphoma. Patients have lower stage & IPI scores compared to symptomatic patients. Potential insight into what could be seen with multi-cancer early detection tests doi.org/10.1002/ajh.27504
@AlbertYunes
Proteomic determinants of renal organ response in light-chain amyloidosis tandfonline.com/doi/full/10.…. The non-amyloid protein constituents of amyloid plaques identified on mass spectrometry may inform a patients’ likelihood of organ recovery. @Taxkourel
1
61